

# Myhealth.stanfordhealthcare.org

however, given the interest across multiple stakeholders for patients to have access to biologic products at a lower cost, the buzz around biosimilars is likely to continue to grow.

[myhealth.stanfordhealthcare.org/activation/lookup](https://myhealth.stanfordhealthcare.org/activation/lookup)

this can result not only in fewer men being subjected to the potential risks of invasive biopsy, but also results in major savings for the society, because unnecessary examinations can be avoided

[myhealth.stanfordhealthcare.org/billing](https://myhealth.stanfordhealthcare.org/billing)

in other states the state has to prove the opposite

[myhealth.stanfordhealthcare.org](https://myhealth.stanfordhealthcare.org)